Floatz logo

18 assets in Cancer Of Unknown Primary Site

Therapeutic assets addressing Cancer Of Unknown Primary Site, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Cancer Of Unknown Primary Site
M.D. Anderson Cancer CenterP3BBB (72)
Fluorouracilum
Cancer Of Unknown Primary Site
Alliance for Clinical Trials in OncologyP2BB (71)
Carboplatin
Cancer Of Unknown Primary Site
Maastricht University Medical CenterP3BB (70)
Cis-Diamminedichloroplatinum Ii
Cancer Of Unknown Primary Site
Emory UniversityP3BB (70)
Cediranib
Cancer Of Unknown Primary Site
City of Hope Medical CenterP2BB (68)
Oxaliplatin
Cancer Of Unknown Primary Site
Alliance for Clinical Trials in OncologyP2BB (68)
Epirubicin
Cancer Of Unknown Primary Site
M.D. Anderson Cancer CenterP2BB (65)
Vinorelbine Ditartrate
Cancer Of Unknown Primary Site
National Cancer Institute (NCI)P1/2B (63)
Tislelizumab
Cancer Of Unknown Primary Site
SOLTI Breast Cancer Research GroupP2B (60)
Atezolizumab
Cancer Of Unknown Primary Site
British Columbia Cancer AgencyP2CCC (53)
Nivolumab
Cancer Of Unknown Primary Site
Instituto do Cancer do Estado de São PauloP2CCC (53)
Pembrolizumab
Cancer Of Unknown Primary Site
M.D. Anderson Cancer CenterP2CCC (53)
cp-506
Cancer Of Unknown Primary Site
Maastricht University Medical CenterP1/2CC (47)
Spartalizumab
Cancer Of Unknown Primary Site
SOLTI Breast Cancer Research GroupP2CC (46)
Veliparib
Cancer Of Unknown Primary Site
National Cancer Institute (NCI)P1CC (46)
COH-29
Cancer Of Unknown Primary Site
City of Hope Medical CenterP1CC (43)
Fapi-46
Cancer Of Unknown Primary Site
Jonsson Comprehensive Cancer CenterP1CC (43)
Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
Cancer Of Unknown Primary Site
City of Hope Medical CenterN/AD (30)